Research programme: synthetic humanised camelid nanobodies - Curie Institute/THERAVECTYS

Drug Profile

Research programme: synthetic humanised camelid nanobodies - Curie Institute/THERAVECTYS

Alternative Names: Synthetic humanised camelid single-domain antibodies - Curie Institute/THERAVECTYS

Latest Information Update: 20 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Curie Institute
  • Developer Curie Institute; THERAVECTYS
  • Class Immunotherapies; Single-domain antibodies
  • Mechanism of Action CD27 antigen inhibitors; Checkpoint kinase inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 14 Apr 2015 Synthetic humanised camelid nanobodies licensed to THERAVECTYS worldwide
  • 14 Apr 2015 Early research in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top